Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) will look for acquisitions. Joseph Ciaffoni, Chief Executive Officer said "Our business development strategy is to diversify the organization in one or more of the following ways: diversifying within pain through commercial stage high-synergy acquisitions, diversifying beyond pain through commercial stage lower-synergy acquisitions, and diversifying into non-opioid pain solutions through the acquisition of late-stage development assets defined as Phase II or later that have the potential to generate revenue in the 2025 to 2027 time frame".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.3 USD | +0.76% | +1.00% | +21.18% |
04-29 | Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER | CI |
04-11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.18% | 1.21B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical to Seek Acquisitions